Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg
TRS-2019-00002051
Quick answer
Invokana 100 mg film-coated tablets, Xigduo 5 mg/850 mg film-coated tablets, Vokanamet 150 mg/850 mg film-coated tablets, Forxiga 10 mg film-coated tablets, Vokanamet 50 mg/1,000 mg film-coated tablets, Invokana 300 mg film-coated tablets, Forxiga 5 mg film-coated tablets, Vokanamet 50 mg/850 mg film-coated tablets, Synjardy 12.5 mg/1,000 mg film-coated tablets, Synjardy 12.5 mg/850 mg film-coated tablets, Jardiance 25 mg film-coated tablets, Synjardy 5 mg/1,000 mg film-coated tablets, Xigduo 5 mg/1,000 mg for Type 2 diabetes mellitus is a Approved program (small_molecule) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ology Bioservices Ireland LTD
- Indication
- Type 2 diabetes mellitus
- Phase
- Approved
- Modality
- small_molecule
- Status
- active